You just read:

Landmark VISTA Trial Shows Significant Long-Term Overall Survival Benefit of VELCADE® (Bortezomib) in Patients With Previously Untreated Multiple Myeloma

News provided by

Janssen Pharmaceuticals NV

12 Dec, 2011, 18:00 GMT